Breakthrough therapies in B-cell non-Hodgkin lymphoma

Annals of Oncology

Volumn 27, Issue 5, 2016, Pages 778-787

  Cheah, C Y ^a,b   Fowler, N H ^c   Wang, M L ^c  

^a Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ibrutinib; Idelalisib; Lymphomas; Novel agents; Treatment; Venetoclax

Indexed keywords

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DUVELISIB; ENTOSPLETINIB; FOSTAMATINIB; IBRUTINIB; IDELALISIB; INEBILIZUMAB; LENALIDOMIDE; NIVOLUMAB; OBINUTUZUMAB; OFATUMUMAB; OTLERTUZUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PLACEBO; POLATUZUMAB VEDOTIN; PREDNISONE; RITUXIMAB; SELINEXOR; TAZEMETOSTAT; TEMSIROLIMUS; UBLITUXIMAB; VENETOCLAX; VINCRISTINE; ANTINEOPLASTIC AGENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ANEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; ATRIAL FIBRILLATION; B CELL LYMPHOMA; BLEEDING; BLOOD TOXICITY; CANCER RESISTANCE; CANCER THERAPY; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CONTUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INTESTINE PERFORATION; LARGE CELL LYMPHOMA; LIVER TOXICITY; LYMPHOCYTIC COLITIS; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PETECHIA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION;

EID: 84964720758     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw029     Document Type: Article

References (122)

1. Cheah CY, Seymour JF, Wang ML. Mantle Cell Lymphoma. J Clin Oncol 2016 Jan 11 [epub ahead of print], pii: JCO635904.
2. Wiestner A. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 2015; 100: 1495-1507.
3. Witzig TE, Nowakowski GS, Habermann TM et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26: 1667-1677.
4. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002; 2: 945-956.
5. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 251-262.
6. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13: 140-156.
7. Flinn IW, Kahl BS, Leonard JP et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406-3413.
8. Gopal AK, Kahl BS, de Vos S et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018.
9. Kahl BS, Spurgeon SE, Furman RR et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.
10. Coutre SE, Barrientos JC, Brown JR et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma 2015; 56: 2779-2786.
11. Cheah CY, Nastoupil LJ, Neelapu SS et al. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood 2015; 125: 3357-3359.
12. Brown JR, Byrd JC, Coutre SE et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-3397.
13. Furman RR, Sharman JP, Coutre SE et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014; 370: 997-1007.
14. Winkler DG, Faia KL, DiNitto JP et al. PI3K-d and PI3K-? inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 2013; 20: 1364-1374.
15. Flinn I, Oki Y, Patel M et al. A Phase 1 evaluation of duvelisib (IPI-145), a PI3K-d, ? inhibitor, in patients with relapsed/refractory iNHL. Blood 2014; 124: 802.
16. Burris HA, Patel M, Fenske T et al. TGR-1202, a novel once daily PI3Kd inhibitor, demonstrates clinical activity with a favorable safety profile lacking hepatotoxicity in patients with CLL and B-cell lymphoma. Hematol Oncol 2015; 33: 119-120.
17. Lanasa MC, Glenn M, Mato AR et al. First-in-human study of AMG 319, a highly selective, small molecule inhibitor of PI3Kd, in adult patients with relapsed or refractory lymphoid malignancies. Blood 2013; 122: 678 (ASH Annual Meeting Abstracts).
18. Phillips TJ, Forero-Torres A, Sher T et al. Interim analysis of a phase I study of INCB040093, a PI3Kd inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies. J Clin Oncol 2015; 33: 8520 (ASCO Meeting Abstracts).
19. Qian C, Lai CJ, Bao R et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res 2012; 18: 4104-4113.
20. Younes A, Patel M, Oki Y et al. A first-in-human trial of CUDC-907, an oral, firstin- class dual inhibitor of PI3K and HDAC, in patients with relapsed/refractory lymphoma and multiple myeloma. Hematol Oncol 2015; 33: 142-143.
21. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107: 13075-13080.
22. Ponader S, Chen SS, Buggy JJ et al. The Bruton tyrosine kinase inhibitor PCI- 32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
23. Ni Gabhann J, Spence S, Wynne C et al. Defects in acute responses to TLR4 in Btk-deficient mice result in impaired dendritic cell-induced IFN-gamma production by natural killer cells. Clin Immunol 2012; 142: 373-382.
24. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
25. Wang ML, Blum KA, Martin P et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. Blood 2015; 126: 739-745.
26. Dreyling M, Jurczak W, Jerkeman M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2015 Dec 4 [epub ahead of print], doi:10.1016S0140-6736(15)00667-4.
27. Wilson WH, Young RM, Schmitz R et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926.
28. Treon SP, Tripsas CK, Meid K et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 2015; 372: 1430-1440.
29. Khurana D, Arneson LN, Schoon RA et al. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol 2007; 178: 3575-3582.
30. Kohrt HE, Sagiv-Barfi I, Rafiq S et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014; 123: 1957-1960.
31. Wang ML, Lee H, Chuang H et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 48-56.
32. Fowler N, Nastoupil L, de Vos S et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter, phase 2 study. Blood 2015; 126: 470.
33. Byrd JC, Harrington B, O'Brien S et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016; 374: 323.
34. Tam C, Grigg AP, Opat S et al. The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood 2015; 126: 832.
35. Walter HS, Rule SA, Dyer MJ et al. A phase I clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood 2016; 127: 411-419.
36. Evans EK, Tester R, Aslanian S et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther 2013; 346: 219-228.
37. Rajasekaran N, Sadaram M, Hebb J et al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonize rituximab-dependent NK-cell mediated cytotoxicity. Blood 2014; 124: 3118.
38. Friedberg JW, Sharman J, Sweetenham J et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
39. Flinn I, Bartlett NL, Blum KA et al. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Blood 2014; 124: 1725.
40. Currie KS, Kropf JE, Lee T et al. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 2014; 57: 3856-3873.
41. Sharman JP, Klein LM, Boxer M et al. Phase 2 trial of entospletinib (GS-9973), a selective Syk inhibitor, in indolent non-Hodgkin's lymphoma (iNHL). Blood 2015; 126: 1545.
42. Barr PM, Saylors G, Spurgeon SE et al. Syk and PI3Kd pathway inhibition resulted in increased rates of pneumonitis: implications for developing future small molecule combinations. Hematol Oncol 2015; 33: 121-122.
43. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
44. Llambi F, Moldoveanu T, Tait SW et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
45. Roberts AW, Seymour JF, Brown JR et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 2012; 30: 488-496.
46. Souers AJ, Leverson JD, Boghaert ER et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013; 19: 202-208.
47. Gerecitano JF, Roberts AW, Seymour JF et al. A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non- Hodgkin lymphoma. Blood 2015; 126: 254.
48. de Vos S, Swinnen L, Kozloff M et al. A Dose-escalation study of venetoclax (ABT- 199/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma. Blood 2015; 126: 255.
49. Tolcher AW, Rodrigueza WV, Rasco DW et al. A phase 1 study of the BCL2- targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73: 363-371.
50. Harb WA, Lakhani N, Logsdon A et al. The BCL2 targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 is active in patients with relapsed or refractory non- Hodgkins lymphoma. Blood 2014; 124: 1716.
51. Niwa R, Hatanaka S, Shoji-Hosaka E et al. Enhancement of the antibodydependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10: 6248-6255.
52. Mossner E, Brunker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402.
53. Golay J, Da Roit F, Bologna L et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood 2013; 122: 3482-3491.
54. Salles GA, Morschhauser F, Solal-Celigny P et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2920-2926.
55. Morschhauser FA, Cartron G, Thieblemont C et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919.
56. Radford J, Davies A, Cartron G et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 2013; 122: 1137-1143.
57. Sehn LH, Goy A, Offner FC et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. J Clin Oncol 2015; 33: 3467-3474.
58. Sehn LH, Chua NS, Mayer J et al. GADOLIN: primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma. J Clin Oncol (Meeting Abstracts) 2015; 33: LBA8502.
59. Czuczman MS, Fayad L, Delwail V et al. Ofatumumab monotherapy in rituximabrefractory follicular lymphoma: results from a multicenter study. Blood 2012; 119: 3698-3704.
60. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486-5495.
61. Coiffier B, Radford J, Bosly A et al. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 2013; 163: 334-342.
62. Furtado M, Dyer MJS, Johnson R et al. Ofatumumab monotherapy in relapsed/ refractory mantle cell lymphoma-a phase II trial. Br J Haematol 2014; 165: 575-578.
63. Czuczman MS, Hess G, Gadeberg OV et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol 2012; 157: 438-445.
64. Czuczman MS, Kahanic S, Forero A et al. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol 2015; 94: 633-641.
65. Matasar MJ, Czuczman MS, Rodriguez MA et al. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade Bcell lymphoma. Blood 2013; 122: 499-506.
66. de Romeuf C, Dutertre CA, Le Garff-Tavernier M et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140: 635-643.
67. O'Connor O, Deng C, Amengual J. A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab. J Clin Oncol 2014; 32: 8524.
68. Sharman JP, Farber CM, Mahadevan D et al. Ublituximab (tg-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and/or refractory CLL and MCL; results of a phase II trial. Blood 2014; 124: 4679.
69. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999; 5: 611-615.
70. Ward E, Mittereder N, Kuta E et al. A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 2011; 155: 426-437.
71. Forero-Torres A, Hamadani M, Fanale MA et al. Safety profile and clinical response to medi-551, a humanized monoclonal anti-CD19, in a phase 1/2 study in adults with relapsed or refractory advanced b-cell malignancies. Blood 2013; 122: 1810.
72. Jurczak W, Zinzani PL, Goy A et al. Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). In ASCO Annual Meeting Proceedings (Abstr 8500). 2015.
73. Zhao X, Lapalombella R, Joshi T et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 2007; 110: 2569-2577.
74. Pagel JM, Spurgeon SE, Byrd JC et al. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR() therapeutic protein, for relapsed or refractory NHL patients. Br J Haematol 2015; 168: 38-45.
75. Gopal AK, Tarantolo SR, Bellam N et al. Phase 1b study of otlertuzumab (TRU- 016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest New Drugs 2014; 32: 1213-1225.
76. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28: 2085-2093.
77. Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 2012; 103: 933-938.
78. Fayad L, Offner F, Smith MR et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 2013; 31: 573-583.
79. Palanca-Wessels MC, Czuczman M, Salles G et al. Safety and activity of the anti- CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory Bcell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015; 16: 704-715.
80. Sharman J, Flinn I, Advani R et al. Two doses of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma: durable responses at lower dose. Hematol Oncol 2015; 33: 177-178.
81. Fanale MA, Forero-Torres A, Rosenblatt JD et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18: 248-255.
82. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458-1465.
83. Jacobsen ED, Sharman JP, Oki Y et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood 2015; 125: 1394-1402.
84. Stathis A, Freedman AS, Flinn IW et al. A phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Blood 2014; 124: 1760.
85. Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30: 631-636.
86. O'Connor OA, Horwitz S, Masszi T et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN- 19) study. J Clin Oncol 2015; 33: 2492-2499.
87. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
88. Kirschbaum M, Frankel P, Popplewell L et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 1198-1203.
89. Sneeringer CJ, Scott MP, Kuntz KW et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA 2010; 107: 20980-20985.
90. Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
91. Knutson SK, Kawano S, Minoshima Y et al. Selective inhibition of EZH2 by EPZ- 6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014; 13: 842-854.
92. Ribrag V, Soria JC, Reyderman L et al. Phase I study of E7438 (EPZ-6438), an enhancer of Zeste-homolog 2 (EZH2) inhibitor: dose determination and preliminary activity in non-Hodgkin lymphoma. Hematol Oncol 2015; 33: 179.
93. Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol 2014; 27: 52-61.
94. Zhang K, Wang M, Tamayo AT et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013; 41: 67-78.e4.
95. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin. Br J Cancer 1996; 74: 648-649.
96. Walker CJ, Oaks JJ, Santhanam R et al. Preclinical and clinical efficacy of XPO1/ CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 2013; 122: 3034-3044.
97. Zhong Y, El-Gamal D, Dubovsky JA et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia 2014; 28: 1158-1163.
98. Chen C, Garzon R, Gutierrez M et al. Safety, efficacy, and determination of the recommended phase 2 dose for the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330). Blood 2015; 126: 258.
99. Garzon R, Wang M, Kuruvilla J et al. Selinexor shows activity in double-hit diffuse large B-cell lymphoma in preclinical models and in patients with relapsed/ refractory double-hit DLBCL. Hematol Oncol 2015; 33: 179-180.
100. Cheah CY, Oki Y, Westin JR, Turturro F. A clinician's guide to double hit lymphomas. Br J Haematol 2015; 168: 784-795.
101. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
102. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
103. Seo SK, Seo HM, Jeong HY et al. Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. Immunol Lett 2006; 102: 222-228.
104. Francisco LM, Salinas VH, Brown KE et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009; 206: 3015-3029.
105. Terme M, Ullrich E, Aymeric L et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res 2011; 71: 5393-5399.
106. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114: 1537-1544.
107. Iwai Y, Ishida M, Tanaka Y et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
108. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.
109. Weber JS, Kudchadkar RR, Yu B et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol 2013; 31: 4311-4318.
110. Armand P, Nagler A, Weller EA et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013; 31: 4199-4206.
111. Westin JR, Chu F, Zhang M et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15: 69-77.
112. Lesokhin AM, Ansell SM, Armand P et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014; 124: 291.
113. Zinzani PL, Ribrag V, Moskowitz CH et al. Phase 1b study of PD-1 blockade with pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBCL). Blood 2015; 126: 3986.
114. Ding W, Dong H, Call TG et al. PD-1 blockade with pembrolizumab (MK-3475) in relapsed/refractory CLL including richter transformation: an early efficacy report from a phase 2 trial (MC1485). Blood 2015; 126: 834.
115. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.
116. Porter DL, Levine BL, Kalos M et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
117. Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015; 33: 540-549.
118. Schuster SJ, Svoboda J, Dwivedy Nasta S et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood 2015; 126: 183.
119. Turtle CJ, Berger C, Sommermeyer D et al. Anti-CD19 chimeric antigen receptormodified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood 2015; 126: 184.
120. Fowler NH, Davis RE, Rawal S et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 2014; 15: 1311-1318.
121. Leonard JP, Jung S-H, Johnson J et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015; 33: 3635-3640.
122. Younes A, Thieblemont C, Morschhauser F et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non- Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014; 15: 1019-1026.